BCX 9930 will discontinued in development programme

This decision allows the company to fully focus its complement inhibitor development efforts on BCX 10013, a potential once-daily, oral Factor D (alternative pathway) inhibitor currently in clinical development, and pursue additional oral compounds for multiple targets across other complement pathways.

“With the new competitor efficacy data presented at ASH, and the limitations preventing us from optimizing the dosing of BCX 9930 for increased efficacy, it is unlikely that BCX 9930 could meet the new standard of care. We have made this decision prior to fully investing in the pivotal development program and commercialization activities, and will focus on our potential best-in-class asset, BCX 10013, and our other programs,” said Jon Stonehouse, BioCryst president and chief executive officer. Patients benefitting from BCX 9930 in the clinical program may remain on therapy. As the program advances, the company plans to offer these patients an opportunity for access to BCX 10013.